Technical Analysis for VIE - Viela Bio, Inc.

Grade Last Price % Change Price Change
grade B 20.74 4.48% 0.89
VIE closed up 4.48 percent on Wednesday, October 16, 2019, on 39 percent of normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Flat
See historical VIE trend table...

Date Alert Name Type % Chg
Multiple of Ten Bullish Other 0.00%
Multiple of Ten Bearish Other 4.48%
Hot IPO Pullback Bullish Swing Setup 10.61%
NR7 Range Contraction 10.61%
NR7-2 Range Contraction 10.61%
Hot IPO Pullback Bullish Swing Setup 8.02%
NR7 Range Contraction 8.02%
New 52 Week Closing Low Bearish 10.61%
Hot IPO Pullback Bullish Swing Setup 10.61%
Inside Day Range Contraction 10.61%

Older signals for VIE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
VIE Chart by TradingView
Basic chart:
Profile
  • Earnings date: ???
  • Sector: Other
  • Industry: Other
Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. Its lead product candidate, inebilizumab, is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.
Medicine Biotechnology Medical Specialties Monoclonal Antibodies Autoimmune And Inflammatory Diseases Humanized Antibody Monoclonal Antibody Therapy Tolerx
Is VIE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Oct 11 Gates-Backed Vir Biotechnology Flops in Trading Debut
Oct 9 The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
Oct 9 Viela Bio inks deal with Mitsubishi Tanabe Pharma to develop inebilizumab in Asia
Oct 9 Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions
Oct 7 Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Oct 4 The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering
Oct 3 UPDATE: Viela Bio jumps 27% in trading debut
Oct 3 Aprea Therapeutics upsizes IPO amid turbulent biotech market
Oct 3 Viela Bio prices IPO at $19
Oct 3 Viela Bio Announces Pricing of Initial Public Offering
See more VIE news...
Indicators
Indicator Value
52 Week High 25.49
52 Week Low 18.2
Average Volume 272,370
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 20.645
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0
MACD Signal Line 0.0
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.95
Resistance 3 (R3) 23.84 22.65 23.42
Resistance 2 (R2) 22.65 21.84 22.71 23.24
Resistance 1 (R1) 21.70 21.33 22.18 21.81 23.06
Pivot Point 20.51 20.51 20.75 20.57 20.51
Support 1 (S1) 19.56 19.70 20.04 19.67 18.42
Support 2 (S2) 18.37 19.19 18.43 18.24
Support 3 (S3) 17.42 18.37 18.07
Support 4 (S4) 17.53